Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of December 14, 2022, the COVID-NMA revised its protocol and stopped including pharmacological interventions trials. The analysis presented in this page includes trials identified and included up to December 14, 2022. Ofnote, different last search date are considered by category. We provide the updated results up to last search defined next to each comparison including all identified reports through our search strategy up to this date.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Summary of Main Results

Summary of the evidence for pharmacological treatment of hospitalized COVID-19 patients identified up to October 17, 2022 is available below.

Summary of Main Results

For earlier editions of the summary of main results, click here

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Access the forest plots for the 363 treatment comparisons .

Search studies

Search by Author Registration number

General characteristics of primary studies

Page: 1 / Sorted by: Most recent ↓
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04445467
VIRCO
McMahon JH, EClinicalMedicine, 2022
Full text
Full text
Commentary
Mixed

Favipiravir

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by a single center in Australia N=199
Some concerns
Details

Full description

NCT05041907
PLATCOV
Jittamala P, medRxiv, 2022
Full text
Commentary
Commentary
Public/non profit

Remdesivir

Standard care

RCT Patients with confirmed COVID-19 (mild) treated by 4 centers in Thailand (3 hospital sites) and Brazil (1 outpatient site) N=136
Some concerns
Details

Full description

NCT05033145
Cabral P, ResearchSquare, 2022
Full text
Commentary
Commentary
Not reported/unclear

Azvudine

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by 5 centers in Brazil N=312
Some concerns
Details

Full description

CTRI/2021/02/030892
Jayanthi CR, Adv Ther, 2022
Full text
Commentary
Private

Inosine Pranobex

Placebo

RCT Outpatients (68%) and inpatients (32%) with confirmed COVID-19 (mild-moderate) treated by 11 centers in India N=416
Some concerns
Details

Full description

IRCT20200504047298N1
Siami Z, Iran Red Crescent Med J, 2022
Full text
Commentary
Public/non profit

Atazanavir/Ritonavir

Lopinavir + Ritonavir

RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Iran. N=103
Some concerns
Details

Full description

NCT04518410
ACTIV-2
Jilg N, Top Antivir Med, 2022 a
Full text
Not reported/unclear

Camostat Mesilate

Placebo

RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by 54 centers in the USA N=215 N/A

Full description

NCT04518410
ACTIV-2
Evering TH, Open Forum Infect Dis, 2021
Full text
Commentary
Not reported/unclear

BRII-196 plus BRII-198

Placebo

RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by multiple centers in the USA, Brazil, South Africa, Mexico, Argentina and the Philippines. N=837
Some concerns
Details

Full description

NCT04518410
ACTIV-2
Taiwo BO, Top Antivir Med, 2022
Full text
Not reported/unclear

SAB-185

Placebo

RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by 42 centers in the USA N=213 N/A

Full description

NCT04575038
CRISIS2
CRISIS2, Unpublished, 2022
Full text
Not reported/unclear

Brequinar

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by 14 centers in USA. N=115
Low
Details

Full description

NCT04709835
NCT04709835, Unpublished, 2022
Full text
Not reported/unclear

AT-527

AT-527 550 mg

Placebo

AT-527 1100 mg

RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by 12 centers in Canada, Greece, Ireland, Latvia, Spain, UK N=100
Some concerns
Details

Full description